Target Product Profile: Measles-Rubella Microarray Patch
As micro-array patches (MAPs, also known as microneedle patches) continue to be developed, their potential advantages of thermal stability and improved ease-of-use, and immunogenicity make them a candidate for use with measles-rubella (MR) vaccines. They have particular advantages that could facilitate delivery and increase coverage for these two vaccines in both low and middle-income countries (LMICs) and high income countries. The following is a Target Product Profile (TPP) for a generic microarray patch (MAP) presentation) with a solid vaccine formulation of a live-attenuated measles-rubella (MR) vaccine (including both coated and dissolvable MAP formats, but not hollow microneedle arrays intended to deliver liquid or reconstituted vaccines). The process of deriving this MR MAP TPP is intended to help focus stakeholders to define acceptable and optimal product attributes, to guide product developers.
Added on: 24 August, 2017